1. Home
  2. SNTG vs DRMA Comparison

SNTG vs DRMA Comparison

Compare SNTG & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sentage Holdings Inc.

SNTG

Sentage Holdings Inc.

N/A

Current Price

$1.70

Market Cap

5.6M

Sector

Finance

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

N/A

Current Price

$1.23

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNTG
DRMA
Founded
2009
2014
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SNTG
DRMA
Price
$1.70
$1.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
17.2K
489.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.95
52 Week High
$4.08
$6.22

Technical Indicators

Market Signals
Indicator
SNTG
DRMA
Relative Strength Index (RSI) 43.53 44.14
Support Level $1.69 $1.14
Resistance Level $2.07 $1.41
Average True Range (ATR) 0.07 0.12
MACD 0.00 -0.03
Stochastic Oscillator 16.07 7.50

Price Performance

Historical Comparison
SNTG
DRMA

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider. The company offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: